A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease

Neurology

Volumn 51, Issue 4, 1998, Pages 1057-1062

  Lieberman, Abraham ^a   Olanow, C W ^b   Sethi, K ^c   Swanson, P ^d   Waters, C H ^e   Fahn, S ^f   Hurtig, H ^g   Yahr, M ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f NEUROLOGICAL INSTITUTE   (United States)

^g GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031664919     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.4.1057     Document Type: Article

References (38)

1. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. BMJ 1974;4: 442-444.
2. Goldstein M, Lieberman A, Lew JY, Asano T, Rosenfeld MR, Makman MH. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA 1980;77:3725-3728.
3. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992; 19(suppl 1):108-112.
4. Olanow CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Dopamine agonists in early Parkinson's disease. Kent, UK: Wells Medical, 1997:37-54.
5. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1:292-296.
6. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Lanes, UK: Parthenon Publishing Group, 1992: 89-112.
7. 3H] spiperone binding. Brain Res 1986;379:294-299.
8. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
9. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
10. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five-year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
11. Lieberman A, Kupersmith M, Estey E, Goldstein M. Treatment of Parkinson's disease with bromocriptine. N Engl J Med 1976;295:1400-1404.
12. Lieberman AN, Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol Rev 1985;37:217-227.
13. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(10 suppl 3):50-54.
14. McDonald RJ, Horowski R. Lisuride in the treatment of parkinsonism. Eur Neurol 1983;22:240-255.
15. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) - a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
16. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997;49(1 suppl 1):S58-S62.
17. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234-245.
18. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39(11 suppl 2):7-10.
19. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
20. Juncos JL, Engber TM, Raisman R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989;25:473-478.
21. Falardeau P, Bouchard S, Bedard PJ, Boucher R, Di Paolo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
22. Gagnon C, Bedard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990;178:115-120.
23. Gomez-Mancilla B, Bedard PJ. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413.
24. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11(1 suppl):200-205.
25. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
26. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(10 suppl 3):32-37.
27. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1989;86:1398-1400.
28. Mytilineou C, Han S-K, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478.
29. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-2464.
30. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507.
31. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723.
32. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by dopa and iron. Neurosci Lett 1992;140:42-46.
33. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
34. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 gm) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
35. Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
36. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.
37. Carvey PM, Ling Z-D. The effects of pramipexole on mesencephalic-derived neurotrophic activity. Neurology 1998 (in press).
38. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992;13:339-351.